2nd Biosimilars Congregation 2013

“Uniting industry leaders to analyse advanced commercial developments & toidentify successful management strategies of Biosimilars”

19th & 20th February 2013, Marriott Regents Park, London UK

 

CONFERENCE BOOKING DETAILS:-

Introductory Offer (3 delegate places for the price of 2):- A huge saving of £ 900 - (Limited seats left) - You can simply email or call and book your conference delegate seats on TEL: + 44 20 3302 4659. Email – delegate.uk@virtueinsight.com

Standard Registration (After 20th January 2013):- Conference Delegate Pass (£ 900 + VAT per delegate) – You can simply email or call and book your conference delegate seats on TEL: + 44 20 3302 4659. Email – delegate.uk@virtueinsight.com

Conference Sponsor & Exhibition Stall Should you wish to Sponsor, or purchase a Exhibiton Stall (Booth) or a paid Speaker Slot, you can simply email your interest and queries to – TEL: + 44 20 3302 4659. Email sponsor.uk@virtueinsight.com

CONFERENCE INTRODUCTION:-

According to Global Industry Analysts Inc.. The global market for biosimilars is forecast to reach US$4.8 billion by the year 2015. By 2020, some $55 Billion worth of biologic patents are due to expire. Key factors driving market growth include patent expiries of key biological drugs, cost containment measures from governments, aging population, and supporting legislations. The recent establishment of regulatory guidelines for biosimilars in the US is expected to add further momentum to the growth of the global biosimilars market. Increasing pressure from governments and insurers for greater biologic competition, there exists an incredible opportunity for biosimilar producers to capitalise on what is set to become the fastest growing sector of the pharmaceutical industry.

The barriers to entry for this lucrative market however require that companies establish and harmonise carefully planned regulatory, clinical and marketing strategies.  Innovators and biosimilar applicants need to find answers to the current myriad of commercialisation questions that face the market. Those to establish their market presence first will dictate the success of companies in the biosimilar space.

Europe holds the highest number of biosimilar approvals, and this number will continue to increase in the near future. Further biologic patent expiries will boost the number of biosimilars to be approved, thereby bringing in an increased number of products that will help increase market size and competition among market participants. The biosimilars market is in the nascent stage of the industry life cycle with limited market and product development experience. However, there is a significant market opportunity from patent expiries. High initial investments are still a major barrier for new entrants. Collaborations among large pharmaceutical companies with financial capabilities and specialty biotech companies with technical expertise are expected. The strong integration of marketing and research and development skills is the key to success in the biosimilars market.

The Conference will bring together top pharmaceutical, biotechnology and regulatory representatives under one roof that will address the key issues of the industry.  Hence, this 3rd Biosimilars Congregation 2013 will look at the multiple facets of biosimilars, ranging from the evolving regulatory landscape and challenges in clinical development, to the legal and economic aspects. By attending this conference you will gain a comprehensive outlook on the key issues surrounding biosimilars. This event will provide an important platform for Biosimilars stakeholders to discuss and share best practices in expediting Biosimilars development.

It gives me great pleasure in welcoming all of you to the Virtue Insight’s 2nd Biosimilars Congregation 2013. I wish and pray that all our efforts will be beneficial to our industries folks at large.

KEY THEMES DISCUSSED AT THIS CONFERENCE:-

  • How should the pharma and generics industries approach the rapidly emerging and developing biosimilar market? The future of next generation Biosimilars
  • How are policy makers shaping the contours of this new generic frontier, and what implications they have for current biologic drug development and patent protection?
  • Next generation monoclonal antibody development and clinical challenges with biosimilar drug development
  • Research-based industry biosimilar strategies
  • Commercial challenges and opportunities - strategies to develop Biosimilars
  • Learn to implement best practices through recent successful strategies and business models – real time case studies
  • Considerations for the analytical similarity assessments when designing a biosimilar development program
  • Determining the right investments & potential returns from Biosimilars
  • General scientific principles in conducting comparative structural and functional analyses, animal testing, human PK and PD studies, clinical immunogenicity assessment, and clinical safety and effectiveness studies
  • Considering the growing importance of biobetters over biosimilars
  • Ascertaining the volume and level of safety data that will be required to prove patient safety and efficacy to facilitate approval
  • Understanding the current regulatory approval standards for Biosimilars in Europe and the US, including for monoclonal antibodies
  • Be part of a major networking opportunity

KEY SPEAKERS:-

  • Paul Tredwell, Head of Biopharmaceuticals, Sandoz
  • Anne Cook, Biologicals Quality Assessor, MHRA
  • Cecil Nick, Vice President, Biotechnology, Parexel
  • Alex Kudrin, Medical Assessor in Licensing of Biological Products, MHRA (Former Medical Director, Takeda Pharmaceuticals)
  • Malcolm I Mitchell, Senior Medical Fellow, Clinical Pharmacology, Eli Lilly
  • Paul Greenland, Biosimilars and Proprietary Marketing Director – EMEA, Hospira
  • Jean-Yves le Cotonnec, CEO, Triskel Integrated Services
  • Mateja Urlep, Founder & CEO, TikhePharma
  • Bruno Flamion, Member, NDA Regulatory Advisory Board
  • Marguérite Mensonides-Harsema, PM Portfolio Development Autoimmune, Medac
  • Sandy Eisen, Chief Medical Officer, Frontline Pharma Consulting
  • Steinar Madsen, Medical Director, Norweigen Medicines Agency
  • Duncan Emerton, Director and Biosimilars Practice Lead, Datamonitor
  • Christopher Holloway, Group Director of Regulatory Affairs, ERA Consulting Group
  • Richard Dennett, Director, Voisin Consulting Life Sciences (France)
  • Peter Wittner, Senior Consultant, Interpharm Consultancy (Former Managing Director Ranbaxy UK)
  • Kristie C. Kuhl, Senior Vice President, Makovsky (USA)
  • Martin Blüggel,
 Chief Business Officer, Protagen Protein Services
  • Ranjith Gopinathan, Program Manager, Life Sciences, Healthcare, Frost & Sullivan
  • Lincoln Tsang, Partner, Arnold & Porter

WHO SHOULD ATTEND:-

CSOs, CMOs, Vice Presidents, Presidents, Heads, Directors, Team Leaders, and Senior Scientists from the following roles:

  • Biopharmaceuticals/ Biotherapeutics
  • Follow on Biologics/Follow on Proteins/Biosimilars
  • Biologics/Biotechnology/ Biogenerics
  • Legal Affairs
  • Intellectual Property
  • Health Economics
  • Pricing and Reimbursement
  • Clinical Immunology
  • Principal Scientist
  • Chief Scientific Officer
  • Process Control and Analytical Technologies
  • Analytical Characterisation
  • Regulatory Compliance
  • Pharmacovigilance
  • Drug Safety & Risk Management
  • Quality Affairs/ Quality Control
  • New Product Development
  • Process Science
  • Portfolio Management
  • Research & Development
  • Business Development
  • Business Operations
  • Scientific Affairs
  • Commercial Affairs
  • Marketing

WHY SHOULD YOU ATTEND:-

2nd Biosimilars Congregation 2013 – “Uniting industry leaders to analyse advanced commercial developments & to identify successful management strategies of Biosimilars”

Get more from the event, with a broader scope bringing the whole communications value chain together. Enjoy and make the best out of our dedicated networking drinks time, meet the leading international vendors showcasing the products of tomorrow in the co-located exhibition. Expand your knowledge of the latest business models and strategies in the high-level conference. Whether you are on the branded or generic side, you cannot afford to miss this opportunity to benchmark your tactics and strategies against the industry leaders who will be the first to traverse the pathway.  Devise an immediate action plan for your biosimilar prosecution and litigation strategies in light of the barriers to entry, research and development costs, and regulatory hurdles, which are balanced against an enormous potential for increased profit margins.

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues

09:30 – Chairperson opening remarks

Kristie C. Kuhl, Senior Vice President, Makovsky (USA) 

MARKET OVERVIEW & ANALISYS

09:40 – Morning Keynote Address – EU regulatory approaches to biosimilars

  • From comparability to biosimilarity
  • Endpoints for biosimilarity clinical trials
  • Extrapolation of indications
  • The safety and immunogeniciity of biosimilars

Bruno Flamion, Member, NDA Regulatory Advisory Board

10:20 – Analysing the next generation monoclonal antibody development & the clinical challenges with biosimilar drug development

  • What are the special requirements for demonstrating biosimilarity of monoclonal antibodies?
  • The advancement of monoclonal antibody technology and the enhancement of oncologic disease therapy by next generation antibody drugs
  • Promising early clinical studies and growing interest
  • The clinical challenges in the biosimilar drug development: manufacturing, preclinical testing, and clinical trial implementation
  • Future opportunities

Sandy Eisen, Chief Medical Officer, Frontline Pharma Consulting 

11:00 – Morning Coffee/Tea & Discussion

CHALLENGES & OPPORTUNITIES

11:20 – Keynote Panel Discussion: Challenges and Opportunities

  • Update on biosimilars in Europe - Current trends for EU biosimilar approvals, and new and future guidelines – Get yourself updated.
  • Biosimilar sales forecast - How large is the opportunity?
  • Opportunities to drive your longer term biosimilars strategy – Possible strategies to enter in emerging markets
  • Identifying a roadmap for success for the EU biosimilars market to minimise costs and maximise return on investment
  • Scientific advice and how to achieve the best dossier
  • Strategies for change: how can we ensure that biosimilars are still safe and efficacious, but also affordable and globally accessible for patients?
  • What characteristics of biosimilar partnerships are critical in developing commercially successful biosimilars?

Moderator:

Kristie C. Kuhl, Senior Vice President, Makovsky (USA)

Panellists:

Alex Kudrin, Medical Assessor in Licensing of Biological Products, MHRA (Former Medical Director, Takeda Pharmaceuticals)

Paul Tredwell, Head of Biopharmaceuticals, Sandoz

Ranjith Gopinathan, Program Manager, Life Sciences, Healthcare, Frost & Sullivan

12:10 – Technology transfer and comparability strategies for biosimilars

  • The nature of the challenge: how to set your sights to meet EU and US regulatory approval
  •  Why technology transfer is essential across all stages of the product development lifecycle
  •  Why comparability is king: prospective issues and mitigation
  •  Case study of a failed technology transfer for a biosimilar product
  •  Getting technology transfer right first time: Putting current biosimilar and ICH guidelines to work

Richard Dennett, Director, Voisin Consulting Life Sciences (France)

12:50 – Networking luncheon

BUSINESS MODEL

14:10 – Capturing the mAb biosimilar opportunity in Germany

  • Historic uptake of generics and biosimilars in Germany: key learnings
  • Drivers and bariers form mAb uptake in Germany: aligning the players
  • mAb opportunity in autoimmune disease: stakeholders and entry strategy

Marguérite Mensonides-Harsema, PM Portfolio Development Autoimmune, Medac

14:50 – Afternoon Keynote Panel Discussion: Biosimilars Development and Impact on Clinical Practice

  • Will biosimilars increase access to biologic therapies in chronic debilitating conditions?
  • How are Biosimilars developed?
  • What are the regulatory challenges and expectations currently in the EU and what can we expect in the US?
  • What does an ideal legal/regulatory framework looks like for a successful Biosimilar model?
  • What impacts will we see in prescribers, payers and patients and what does this mean for drug developers?
  • Analysis on the current situation in terms of biosimilar infliximab

Moderator:

Kristie C. Kuhl, Senior Vice President, Makovsky (USA)

Panellists:

Malcolm I Mitchell, Senior Medical Fellow, Clinical Pharmacology, Eli Lilly

Steinar Madsen, Medical Director, Norweigen Medicines Agency

Sandy Eisen, Chief Medical Officer, Frontline Pharma Consulting

15:40 – Afternoon Tea/Coffee

16:00 Demonstrating Biosimilarity – Considerations on the Comparability Exercise

  • Quality strategies in developing Biosimilars – From Clone pool selection to GMP production
  • Regulatory aspects of structural comparability
  • State-of –the-art analytics for CMC section
  • Actual Case studies for Demonstrating Biosimilarity

Martin Blüggel,
Chief Business Officer, Protagen Protein Services

16:40 – Chairperson’s closing remarks and end of conference

Kristie C. Kuhl, Senior Vice President, Makovsky (USA)

16:50 – 18:00 Networking Drinks Session

08:30 – Coffee and registration – An opportunity to meet and to network with your conference colleagues

09:30 – Chairperson opening remarks

Duncan Emerton, Director and Biosimilars Practice Lead, Datamonitor

BUSINESS MODELS

09:40 – Morning Keynote Address 1: "Opportunities in European Biosimilars Market"

Ranjith Gopinathan, Program Manager, Life Sciences, Healthcare, Frost & Sullivan

10:20 – Key drivers for the development of biosimilars

  • What are the key opportunities in the emerging markets?
  • Analysing the key action plan necessary to fast-track the development of current biosimilars market
  • Surveying the battlefield: how are the key players lining up?
  • Preparing a ‘biologic experience’ for biosimilar uptake in Europe

Jean-Yves le Cotonnec, CEO, Triskel Integrated Services

11:00 – Morning Coffee/Tea & Discussion

11:20 – Panel Discussion - Biosimilars vs. Biobetters

  • Considering the growing importance of biobetters over biosimilars
  • Considering and comparing facts like – ROI, gaining competitive edge, faster approval timeline and Innovator responses to the threat of competition
  • Successful methods for biobetter developments
  • Partnering trends of Biosimilars & Biobetters in emerging markets
  • What different development approaches are companies taking?
  • What will be the involvement of companies in the U.S./EU vs. those in developing countries?

Moderator:

Duncan Emerton, Director and Biosimilars Practice Lead, Datamonitor

Panellists:

Anne Cook, Biologicals Quality Assessor, MHRA

Paul Greenland, Biosimilars and Proprietary Marketing Director – EMEA, Hospira

Jean-Yves le Cotonnec, CEO, Triskel Integrated Services

12:10 – Branding and Promotional Considerations for Biosimilars

  • How distinct does the follow-on product name have to be from the original?
  • New Paradigm in Strategic Partnerships for Follow-on Biopharmaceutical Development
  • The benefits and drawbacks of a unique nonproprietary name to distinguish biosimilars from reference products
  • What are the expected commercialization challenges and discover various ways to overcome them
  • Protecting your biologic through enforcement and risk management strategies
  • Why is patent risk higher for biopharmaceuticals than traditional small molecules?

Mateja Urlep, Founder & CEO, TikhePharma

12:50 – Networking luncheon

CLINICAL STUDIES FOR BIOSIMILARS

14:10 – Afternoon Keynote Address – Determining the type & volume of clinical data that is essential for establishing biosimilarity - An EU, FDA, and RoW perspective

  • What will FDA require in terms of clinical testing?
  • Striking a balance between requiring larger and more sophisticated trials and facilitating market entry for biogenerics 
  • Understanding the patient perspective in the biosimilar conversation

                o    Biologic and biosimilar safety and efficacy
                o    Pharmacovigilance: collecting, monitoring, researching, assessing and evaluating adverse events
                o    Cost to the patient
                o    Therapeutic substitution issues
                o    Barriers to care

  • What level of support will FDA require to get approval?
  • Extrapolating data obtained in clinical trials for a reference product to support biosimilar applications

Cecil Nick, Vice President, Biotechnology, Parexel

PRICING & REIMBURSEMENT

14:50 – Pricing and Reimbursement of Biosimilars – Identifying successful access & pricing strategies

  • Challenges and threats in terms of market   access – identify and break through
  • Making sure in the development plan that a biosimilar gets favourable pricing and market access evaluation at launch?
  • Determining the right investments & potential returns from Biosimilars
  • Lessons from the EU Pricing Challenges for biosimilars entrants
  • Coping with cuts in government expenditure
  • Ensuring long-term sustainability in Global healthcare, by reducing the cost of biologics

Peter Wittner, Senior Consultant, Interpharm Consultancy (Former Managing Director Ranbaxy UK)

15:30 – Afternoon Tea/Coffee

REGULATION OVERVIEW & UPDATE

15:50 – Panel Discussion: The developing regulatory framework in advanced and developing markets – for Today & Tomorrow

  • A brief recap of recent regulatory developments in Europe and the United States
  • Current Biosimilars practices in UK and examining various methods for improvement
  • Assessing the government incentives and initiatives currently in place and planned, around EU biosimilars
  • Analysing the developing biosimilars regulatory framework in the U.S.
  • Reviewing and applying comparability studies by the FDA
  • Legal for Biosimilars - Turning antitrust laws to your advantage in the generics and biosimilars

Moderator:

Christopher Holloway, Group Director of Regulatory Affairs, ERA Consulting Group

Panellists:

Lincoln Tsang, Partner, Arnold & Porter

Peter Wittner, Senior Consultant, Interpharm Consultancy (Former Managing Director Ranbaxy UK)

16:30 – Chairperson’s closing remarks and end of conference

Duncan Emerton, Director and Biosimilars Practice Lead, Datamonitor

16:40 – End of the 2nd Biosimilars Congregation 2013

ORGANIZED BY

Virtue Insight

Virtue Insight equips business professionals around the world with the latest indepth industry knowledge and provides networking opportunities in the telecom, infrastructure and pharmaceutical industry. Our aim is to provide a platform to share knowledge and insights and provide our event attendees to network effectively and deliver maximum ROI by make new business alliances. We strive to produce high quality conferences which include the latest topics which are delivered by world class leaders of the industry.

Our motto is to offer our customers the expertise and connections for a profitable business. Our events encompass an optimum chance to gain maximum value in terms of networking and an opportunity to sponsor and exhibit to attract new business alliances.

BRONZE SPONSOR

Quintiles

Quintiles is the world’s leading biopharmaceutical service provider With a network of more than 27,000 professionals working in more than 80 countries, we have helped develop or commercialize all of the top 50 best selling drugs on the market. With extensive therapeutic, scientific and analytics expertise, we help biopharmaceutical and health sciences
customers navigate the increasingly complex landscape with more predictability to enable better outcomes.

We address the needs of the biopharmaceutical industry and broader healthcare industries, including payers and providers. We use our expertise and insights to help customers optimize the value of their drug development, commercialization and health care delivery.

We can support our customers from initial human testing through patent expiration, from strategy through planning and execution. Through our extensive range of services, we solve our customers’ biggest challenges: decreasing costs, improving productivity, and saving time. The broad scope of our services helps our customers rapidly assess the viability of a growing number of potential new therapies, cost-effectively accelerate development of the most promising ones, successfully launch new products to market and evaluate their impact and appropriate use in patients.

All along, we work with an unwavering dedication to patients, safety and ethics.

PROMOTIONAL LITERATURE DISTRUBUTION

ByteMindz

We are an emerging company with an aim of providing business solutions across Web Designing, Web Application Development, Software Development, Multimedia Services and Mobile Solutions.

We work on a diverse product line of services which are developed compatible for various frameworks, providing a complete project design and development using our high standard technical team. We believe not only to produce exceptional in-house application we focus also on enhancing the commercial values for the customer end user applications. We extend our power of imagination across various verticals of IT services making the customer highly satisfied by providing an individual attention to each and every customer irrespective of the high, medium & large scale of organization.

We also provide value added service that includes the service apart from our core standard service, we give a valuable testing unit and a complete support from our back end .We would like to hear from the customer periodically and we monitor our growth based on the customer quotes & comments and work hard on fixing those reported problems and include the fixes in our library based on the system designs and code compatible requirements.

We generally release our product to our customer in a three phases, initially on the first phase with the beta version to make the customer to have a look in to our product whether their requirement is achieved. On the next phase we roll out our RC (Release Candidate) version of our product with all the fixes and features completely include, then on the third phase we deliver our final release on the promised date of delivery. On all these phase we completely integrate our technical and management resources with the customer dedicatedly making us much flexible to serve the customer to their maximum All these development life cycle has been maintained in a limited set of budget making the customer highly satisfied.

MARKETING SPONSOR

Bio World

BioWorld® Today, the news source of record for the biopharmaceutical industry, is read by biotechnology professionals worldwide for its hard-hitting, objective news reporting. BioWorld publishes information that is researched and written by the top business and science reporters in the industry. With nearly 20 writers spread throughout eight countries, BioWorld covers news on public companies and hard-to-find information on private companies. This news coverage of the biotechnology industry is 100 percent original and available only at BioWorld.

Daily news coverage includes:

  • Therapeutic product development from early to late stage
  • Strategic alliances, mergers and acquisitions
  • Corporate financings, both public and private
  • Biotech company advancements and setbacks
  • Scientific milestones
  • Global regulatory updates
  • Profiles of new and mature biotech and specialty pharmaceutical firms
  • Big pharma’s growing involvement in biotech

BioWorld Today is the industry’s most respected news source for more than 20 years

SUPPORTED BY

Pharmaphorum

pharmaphorum is the primary facilitator of thought leadership and innovation within pharma. We support the next generation of pharmaceutical industry leaders through producing, curating and publishing media that will help pharma embrace the challenges of being a healthcare solutions provider in the 21st century.

Our services include:

  • Publication of interesting new written, audio and video content addressing critical pharma issues from around the world.
  • Showcasing key service providers who can work with pharma executives to forge the business models of the future.
  • Curation of global news, industry events and job opportunities within pharma.
  • Production of written, audio and video content for publication on pharmaphorum or client channels.
  • Advice and support on the use of social media within pharma to effectively connect companies, improve PR and share innovation.

Visit www.pharmaphorum.com today to discover what is shaping the future of your industry.

PharmaVoice

PharmaVOICE magazine, reaching more than 17,500 U.S.-based life-sciences executives, is the forum that allows business leaders to engage in a candid dialogue on the challenges and trends impacting the industry. PharmaVOICE, and its supporting VIEW publications, provide readers with insightful and thought-provoking commentary in a multiple-perspective format through forums, topics, and articles covering a range of issues from molecule through market. PharmaVOICE subscribers are also kept abreast of the latest trends and information through additional media resources, including WebLinx Interactive WebSeminars, Podcasts, Videocasts, White Papers, E-Surveys and e-Alerts. Additionally, PharmaVOICEMarketplace.com provides a comprehensive directory of products, services, and solutions for the life-sciences industry.

To Raise Your VOICE, contact feedback@pharmavoice.com

Going to meet

Business Wire

Business Vibes

BusinessVibes is a global B2B networking site which is home to 600+ associations and 200,000+ companies in 92 countries worldwide.We use a social networking model to promote business partnerships between companies in the US, Europe, India, China, and other major economies.

Broadband Wireless Consortium of India

Broadband Wireless Consortium of India (BWCI) is a national forum for addressing various aspects of Broadband Wireless Technologies including technology development, standardization, trials, deployment and regulation. The consortium, created as a non-profit organization, comprises of major stakeholders in the Indian telecom sector including operators, equipment vendors, technology services providers, semiconductor companies, R&D institutions, academia and government agencies. BWCI strives to develop consensus on the Broadband Wireless requirements of India and present them in global standardization forums. BWCI also facilitates co-operative efforts by members to build technology demonstrators, showcase system performance, fine-tune specifications, and enable rapid deployment of new solutions.

Clocate

Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location.  Each event includes detailed information, like, description, dates, location, map, prices, link to the official event's  website and more...
If you search for a conference or exhibition in areas such as Industry and manufacturing, Health and medicine, Technology and IT, Business and finance, sciences, education, services (banking, insurance, tourism, Hospitality and more), government, environment, life style and arts, you'll find it in Clocate.com

Business News

Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our “Growth Partnership” supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

  • The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.  
  • The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible.  This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.  

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?  

Good Discussion about commercial Challenges and lessons with 1st class biosimilar products and challenges/ development, regulatory and commercial with biosimilars MABs

Alex Kudrin
Medical Assessor in Licensing of Biological Products, MHRA

Excellent cross section of up to date & future directions of Biosimilars

Richard Dennet
Director, Voisin Consuting Lifesciences

For access to the presentations for this conference, please email us at presentations@virtueinsight.com

Our potent conference agenda delivering the latest information and the world class leaders as speakers attract delegates to attend from around the world. We aim for our attendees to be equipped with knowledge of latest developments and enable them to network with the industry key personnel.

To book a Delegate Place, India - delegate@virtueinsight.com United Kingdom - delegate.uk@virtueinsight.com

Designed By ByteMindz
Close
Welcome
You have been registered successfully!
Close
Close
Enter Password
Submit Close